Navigation Links
FDA approves the NovoTTF-100A system for the treatment of patients with recurrent glioblastoma multiforme (GBM) brain tumors
Date:4/15/2011

WASHINGTON, D.C. April 14, 2011 Novocure today announced that the U.S. Food and Drug Administration (FDA) approved the NovoTTF-100A System (NovoTTF) for the treatment of adult patients with glioblastoma multiforme (GBM) brain tumors, following tumor recurrence after receiving chemotherapy. The portable, wearable device delivers an anti-mitotic, anti-cancer therapy as patients maintain their normal daily activities. The NovoTTF is a novel, first-in-class treatment option for patients and physicians battling glioblastoma.

"Our device provides patients and physicians with a novel, non-invasive alternative to chemotherapy that is safe and effective," said Eilon Kirson, M.D., Ph.D., Novocure's Chief Medical Officer. "The device allows for continuous treatment without the usual, debilitating side effects that chemotherapies inflict on recurrent GBM patients and indirectly on their families."

Results from a 237 patient randomized pivotal trial demonstrated that compared to patients treated with chemotherapy, NovoTTF treated patients achieved comparable median overall survival times, had fewer side effects, and reported improved quality of life scores.

Glioblastoma is the most aggressive and most common form of primary brain tumor in the United States. The disease affects approximately 10,000 Americans each year. The median overall survival time from initial diagnosis is 15 months with optimal therapy, and median survival from the time of tumor recurrence is only three to four months without additional effective treatment. The disease is widely recognized as one of the most aggressive and deadly forms of cancer.

"We move forward from today proud of the efforts and accomplishments of our team, thankful to our investors for their support and guidance, and humbled by the trust of our patients and physicians." said Asaf Danziger, CEO of Novocure. "Our next task is to make NovoTTF therapy available as a treatment option for al
'/>"/>

Contact: Frank Leonard
frank@novo-cure.com
917-656-3518
Edelman Public Relations
Source:Eurekalert

Page: 1 2

Related biology news :

1. FDA approves trial for type 1 diabetes treatment by Ben-Gurion U. and U. Colorado
2. DFG approves 12 new collaborative research centers
3. DFG approves funding for 17 new collaborative research centers
4. Death -- not just life -- important link in marine ecosystems
5. Stress wrecks intestinal bacteria, could keep immune system on idle
6. Common nanoparticles found to be highly toxic to Arctic ecosystem
7. A better understanding of the aging immune system
8. E. coli an unlikely contaminant of plant vascular systems
9. Human impacts on the marine ecosystems of Antarctica
10. A new signaling pathway of the immune system is elucidated
11. MIT systems biologists use computer models to predict animal cell behavior
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2015)... , Feb. 5, 2015  Marken is starting its ... and has launched a new marketing campaign to solidify ... (CLO).  The new campaign focuses on First ... and shipments. The first headline in the ... Marken,s priorities with its client,s priorities. Marken recognizes the ...
(Date:2/5/2015)... 2015 New Market Research Reports ... Forecasts To 2020 has Been Added to GrandViewReseach.com Report ... expected to reach USD 5.10 billion by 2020, according ... IR cameras help identify the site of tissue damage ... surging demand in medical imaging applications. They have been ...
(Date:2/5/2015)... VIEW, Calif. , Feb. 3, 2015 /PRNewswire/ ... printer technology, demand from industries such as consumer ... global market for surface mount technology (SMT) screen ... equipment to automatic control will push the adoption ... dispensers will remain steady as glue dispensers are ...
Breaking Biology News(10 mins):Marken Launches New Patient-Centric Campaign 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3
... observed exotic behaviour from beryllium oxide (BeO) when they ... in this way, the electrons in the BeO appeared ... of their environment. The researchers, measurements show changes in ... rapid melting around the firing line of the heavy ...
... medieval means of destruction, but for some plants, they ... seeds greater distances by catapulting can provide selective advantages, ... escape from certain threats. In new work ... Journal of Botany ( http://www.amjbot.org/cgi/reprint/97/10/1595 ), Dr. Ellerby, ...
... release is available in Spanish . Scientists ... strategies to ward off cattle fever ticks that are crossing ... ticks transmit bovine babesiosis, commonly known as Texas cattle fever, ... Agricultural Research Service (ARS) scientists in Kerrville, ...
Cached Biology News:Electrons get confused 2How some plants spread their seeds: Ready, set, catapult 2Getting rid of cattle fever ticks 2
(Date:2/27/2015)... Australia , Feb. 27, 2015 Bionomics ... from the DisrupTOR-1 trial of BNC105 in patients with ... in Orlando, Florida . The data ... of the City of Hope Comprehensive Cancer Center in ... The new data identifies Ferritin and ...
(Date:2/27/2015)... 27, 2015 Cytokinetics, Incorporated (Nasdaq: CYTK) ... 28 with patients and health care advocates in the ... Disease Day®. Rare Disease Day is dedicated to ... to the special challenges faced by patients with rare ... is proud to stand alongside patients and caregivers representing ...
(Date:2/26/2015)... 2015 S&P Capital IQ (MHFI) announced today ... on MabVax Therapeutics Holdings Inc . ... biotechnology company focused on the development of vaccine and ... treatment of cancer. MabVax has discovered a pipeline of ... responses generated by patients who have been immunized against ...
(Date:2/26/2015)... - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: ... and commercializes proprietary technologies and products for advanced microarray ... the fiscal first quarter ended December  31, 2014. All ... (CAD), unless otherwise stated. "During the ... our existing customers and add to our sales pipeline," ...
Breaking Biology Technology:New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 6S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5SQI Diagnostics Reports First Quarter Financial Results 2SQI Diagnostics Reports First Quarter Financial Results 3SQI Diagnostics Reports First Quarter Financial Results 4SQI Diagnostics Reports First Quarter Financial Results 5SQI Diagnostics Reports First Quarter Financial Results 6
... 2011 Reportlinker.com announces that a new ... catalogue: Industrial Biotechnology ... http://www.reportlinker.com/p0655292/Industrial-Biotechnology-China-News-1109---Annual-Subscription.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Renewable_energy ... of Biotechnology Industry to be published in ...
... October 12, 2011 - Two pivotal ... with ulcerative colitis and Crohn,s disease - ... on the development and commercialisation of late-stage, mineral-derived hospital ... today announced that the first patients have been treated ...
... has selected a University of Pennsylvania team as a ... awards. The I-Corps Awards recognize research that has the ... resources. "The idea is to facilitate the transfer ... into the commercial world," said team member Charlie Johnson, ...
Cached Biology Technology:Industrial Biotechnology China News 1109 - Annual Subscription 2Industrial Biotechnology China News 1109 - Annual Subscription 3Shield Therapeutics Initiates AEGIS 1 and AEGIS 2 Phase 3 Studies of ST10 2Shield Therapeutics Initiates AEGIS 1 and AEGIS 2 Phase 3 Studies of ST10 3Penn team wins entrepreneurial innovation award 2
... Bionic Buffer is a unique ... and TAE (TRIS acetate-EDTA) electrophoresis buffers. ... runs, extremely rapid running times, and ... use in gel electrophoresis after dilution ...
... Continuous flow of media and other ... little lab space, The speed of each ... and flow set points, are exactly maintained. ... equipped with variable tube types, which allows ...
...
... is most widely used in combination ... differentially stain nucleic acids following polyacrylamide ... solution, Pyronin Y stains RNA red, ... Chem comp: Dye content ...
Biology Products: